undamentalytics Newsletter
Sign in

Anaptysbio, Inc balance sheet

At the end of fiscal 2025, Anaptysbio, Inc had total assets of $364m and shareholders' equity of $37.2m. It held $138m in cash against $0 of debt: net cash of $138m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents525181114171250496713623138134
Receivables—10000117413426
Total current assets—58253434378397554447407432350198
Total assets—62329509435417643610452484364317
Accounts payable—225164235444
Total current liabilities—614223020162637453935
Total debt007810000000
Shareholders' equity−35−3830848640539735626288713711
Net debt (negative = net cash)−52−51−74−106−170−250−496−71−36−23−138−134
Shares outstanding—3m24m27m27m27m28m29m27m30m28m30m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ANAB vs RYTMANAB vs IDYAANAB vs PBYIANAB vs LGND

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Anaptysbio, Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Anaptysbio, Inc.